Rhinovirus Inhibits Antigen-Specific T Cell Proliferation through an Intercellular Adhesion Molecule-l-Dependent Mechanism
To determine whether binding of human rhinovirus (HRV) to intracellular adhesion molecule-I might disrupt airway immune processes, effects of a major HRV group, HRV-16, on T cell proliferation and cytotoxicity were defined. HRV (1-10 TCIDso/cell)significantly inhibited T cell proliferation induced by antigen but not proliferation secondary to mitogens, interleukin-2, or an irradiated allogeneic T cell line. Noninfectious (UV-irradiated) HRV had similar effects. Inhibition of T cell proliferation was dependent on HRV binding to intercellular adhesion molecule-l on monocytes, indicating that the virus interferes with lymphocyte activation indirectly through effects on antigenpresenting cells. In addition, HRV inhibited T cell cytotoxic responses but not NK cell activity. If these effects also occur in vivo, the resulting disturbance in local airway immunity could increase the chances of successful viral replication, and might also be a factor in the pathogenesis of secondary viral or bacterial respiratory tract infections.
Many viruses, including respiratory syncytial virus, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, measles, and poxviruses, have evolved means to enhance replication and subsequent transmission by suppressing antiviral immune responses [1, 2] . A by-product of local or systemic immune suppression by these viruses is an increased susceptibility to secondary bacterial or viral infections.
Human rhinovirus (HRV), one of the most successful pathogens, causes~30%-50% of upper respiratory infections worldwide [3] and is also associated with local infectious complications, such as otitis media and sinusitis [4] [5] [6] [7] . Factors that contribute to the abundance of HRV infections include a remarkable degree of antigenic variation and a fast replicative cycle typical of most RNA viruses [8] . Another interesting feature of HR V is that 90% of the > 100 serotypes must bind to intracellular adhesion molecule-l (ICAM-l) to replicate within host cells [9] [10] [11] . Although HRV replication has been documented in only a few cell types, lCAM-I may be expressed on the surface of many different cells, including those that are active in respiratory immune responses, such as monocytes and airway macrophages [12] [13] [14] , dendritic cells [15] , airway eosinophils [16] , mast cells [17] , B lymphocytes [18, 19] , and activated T lymphocytes [18] .
The natural ligand for lCAM-l is lymphocyte functionassociated antigen (LFA-l) [20] , designated CDlla/CDI8. Although ICAM-1/LF A-1 interactions are important in mediating cellular adhesion [21] , it is also clear that interaction of these surface receptors generates costimulatory signals, which include activation of CD4 T cells [22] [23] [24] [25] , cytotoxicity mediated by T cells and lymphokine-activated killer cells [26] [27] [28] [29] , and T cell-dependent B cell activation [18] . The binding sites on the lCAM-l molecule for LFA-l and HRV overlap [30] , and as a result, HRV can block lCAM-l-dependent interactions between T cells and cytokine-treated dermal fibroblasts [31] .
It has been hypothesized that HRV may also interfere with lCAM-l/LFA-I binding on leukocytes and, thus, disrupt immune responses that are dependent on this interaction. An important consequence of these effects could include disruption oflocal airway immunity and inhibition of anti -HRV responses, which would increase the chance of productive viral replication. To test this hypothesis, the following experiments were done to determine the effects of HRV on T cell proliferative and cytotoxic responses.
Materials and Methods
Reagents and cells. Stimuli used in the T cell proliferation assay included tetanus toxoid (Connaught, Swiftwater, PA), varicella antigen (VZ; Russell Tomar, Department of Pathology, University of Wisconsin), streptokinase, (KabiVitrum, Stockholm), ragweed and Candida extracts (Hollister-Stier, Elkhart, IN), phytohemagglutinin and concanavalin A (ConA; Sigma, St. Louis), and recombinant human interleukin (IL)-2 (R&D Systems, Minneapolis). TK6 cells (American Type Culture Collection, Rockville, MD) or peripheral blood mononuclear cells (PBMC) from a healthy unrelated donor were irradiated (50 Gy) and then frozen at -70°C for use as stimulators of allogeneic T cell proliferation. Anti-lID J 996; 174 (December) ICAM-1 monoclonal antibody (MAb; C78.4A) [32] was provided by Jeffrey Greve (Miles Laboratories, New Haven, CT). WIN 54954, a peptide that binds to the canyon region of HRV and blocks binding to ICAM-l and subsequent uncoating of the virus [33] , was provided by Dan Pevear (Sterling Winthrop, Collegeville, PA).
PBMC were obtained by ficoll separation of heparinized whole blood obtained from normal volunteers. Plasma was centrifuged to remove platelets and then used in proliferation experiments. After two washes with PBS and 0.02% EDTA, the cells were resuspended in RPMI with 25% autologous serum, 50 U/mL penicillin, and 50 zzg/ml. streptomycin. Cell viability, as estimated by staining with trypan blue, was consistently >95%. so TCIDso/mL, as measured by inoculating serial dilutions of virus suspension in HeLa (HRV-16) or WI-38 (HRV-49) cells, were stored at -70°C until needed. Supernatant from uninfected Hel.a cell cultures was also frozen in aliquots to be used as a negative control in some experiments.
The HRV-16 suspension was partially purified [34] for some experiments to remove ribosomes and soluble factors of HeLa cell origin. HRV-16 suspension, as described above, was treated with 20 j.lg/mL RNase A (Sigma) at 35°C for 20 min, and then 1% sodium sarcosyl and 1 j.lLlmL 2-mercaptoethanol were added. This mixture (27 mL) was transferred to a 30-mL ultracentrifuge tube, underlaid with 3 mL of a solution containing 20 mM TRIS acetate, 1 MNaCl, and 30% (wt/vol) sucrose, and then centrifuged (25,000 rpm at 16°C) for 5 h to pellet the virus. The supernatant was discarded, and the pellet was resuspended in medium, which was then frozen at -70°C until needed.
Noninfectious HRV-16 or HRV-49 suspensions were prepared by irradiating the virus suspension with UV light. To accomplish this, HRV suspension was placed into a plastic petri dish so that the depth was~5 mm. An 8-W UV lamp (254 nm) was positioned 10 em from the virus suspension, and the suspension was irradiated for 15 min while being gently agitated every 4-5 min. This procedure yielded virus that was noninfectious in HeLa cell cultures, but it could induce proliferation of PBMC or HRV-specific T cell clones.
T cell proliferation assays. Human PBMC (IO'vwell) were added to 96-well microtiter plates (Coming Lab Sciences, Coming, NY) in the presence of either 0.04 LfU/mL tetanus toxoid, 125 U/ mL streptokinase, 1:100 dilution of varicella zoster antigen, 5 X 10 4 irradiated allogeneic PBMC or TK6 cells, or 100 U/mL IL-2 for 6 days in the presence or absence of live or UV -irradiated HRV-16 (10 TCIDso/cell). For experiments involving T cell clones, irradiated mononuclear cells functioning as antigen-presenting cells (APCs, lOs cells/well) were incubated for 48 h along with T cell clones specific for HRV-49 (1-2 X 10 4 cells/well) and antigen (l TCIDsoicell UV-irradiated HRV-49) in the presence or absence of live or UV-irradiated HRV-16 (10 TCIDso/APC), purified HRV-16 (l0 TCIDso/APC), or anti-ICAM-l MAb (20 j.lg/mL).
To quantitate thymidine incorporation into DNA, [3H]thymidine (1 p,Ci/well) was incubated with each sample for an additional 18 h, the samples were transferred onto glass paper by use of an automated harvester (Skatron, Lier, Norway), and counts per minute (cpm) were measured in a scintillation counter (Packard, Meriden, CT). Mean cpm were determined for triplicate or quadruplicate wells, and the stimulation index (SI) was calculated by dividing the mean cpm of an antigen or mitogen-stimulated sample by the mean cpm of cells incubated with medium alone. Significant proliferation was defined as SI ;0=:2 for PBMC and SI ;0=:3 for T cell clones. Samples of PBMC that proliferated to HRV-16 alone were not included in subsequent analyses because virus-specific proliferation would have obscured the inhibitory effect ofthe virus on proliferation due to other stimuli.
Cytotoxicity assays. NK cell activity and T cell cytotoxicity were determined using chromium release assays according to standard protocols [35] . In brief, the NK cell assay was done by incubating (37°C) PBMC with slCr-Iabeled K562 cells (103/well) at 4 different effector-to-target cell ratios in the presence of partially purified HRV-16 (5 X 10
6 TCIDso/ml) or medium alone. After a 4-h incubation, free SICr in cell culture supernatants was quantitated in a gamma counter, and lytic units per 10 7 cells were calculated according to the formula 10
, where E:T2O'Yo is the effector-to-target cell ratio producing 20% lysis, and t is the number of target cells per well.
For T cell cytotoxicity, PBMC (2 X 10 6/mL) were sensitized by incubation (6 days, 37°C, 5% CO 2 ) with irradiated (10,000 rads) allogeneic Epstein-Barr virus-transformed B cells (106/mL). After being washed, sensitized cells were incubated (4 h, 37°C) in round-bottomed 96-well plates along with slCr-Iabeled target cells (2.5 X 10 3 cells/well) at four different effector-to-target cell ratios in the presence of either partially purified HRV-16 (5 X 10 6 TCIDso/mL) or medium alone. Chromium release was converted into lytic units as described above.
Incubation of isolated T cells and monocytes with HR V-16.
T cells were isolated from PBMC by use of a T cell enrichment column (R&D Systems), yielding 75%-95% CD3+ cells, 5%-24% CD56+CD3-cells, and < 1% CDl4 or CD20 cells. Monocytes were isolated by incubating (4 h, 37°C) 100 f.lL of PBMC (2 X 10 6 cells/mL in RPMl) in flat-bottomed 96-well plates. Nonadherent cells were removed by vigorous pipetting with PBS. The T cells and monocytes were then incubated separately overnight with either HRV-16 (10 TCIDso/cell) or medium alone. After unbound virus was washed away, the cells were recombined and stimulated with tetanus toxoid (0.04 LfU/mL). eH]thymidine was added on day 6, and incorporation into DNA was measured on day 7.
Use of WIN 54954 to inhibit HRV-16-ICAM-l binding. In preliminary experiments, WIN 54954 inhibited HRV-16-ICAM-I binding on HeLa cells, as determined by measuring ICAM-1 receptor occupancy by flow cytometry (table 1) . Hel,a cells were incubated (16 h, 37°C) with HRV-16 (10 TCIDso/cell) or medium alone in the presence 0-20 j.lg/mL WIN 54954. HeLa cells had a high baseline expression of CD54, but binding of labeled CD54 antibody was blocked by incubation with HRV, as indicated by a reduction in the median channel fluorescence (from 50.8 to 7.1). WIN 54954 at concentrations of2-20 /l.g/mL, which had no direct effects on CD54 expression, blocked the HRV -mediated reduction in CD54 binding.
On the basis of the preliminary data and previously published reports [33, 36] , WIN 54954 was used as a specific inhibitor of cells/mL) were incubated for 24 h with lipopolysaccharide (LPS; 0.1-100 ng/mL) in the presence or absence of 10 TCID50/mL HRV-16. TNF-a was measured in supernatants using an ELISA (BioSource International, Camarillo, CA) according to the manufacturer's instructions. Statistical analysis. Results from T cell proliferation experiments were expressed in terms of the SI (100 X [cpm stimulated! cpm control]), and these values were log-transformed before analysis. Normally distributed data sets were analyzed with the paired t test, and nonparametric data sets were analyzed with the MannWhitney rank sum test. P~.05 was considered significant. All computations were done with the aid of computer software (SigmaStat; Jandel Scientific, Costa Mesa, CA).
Results

Effect of HRV on T cell proliferation.
To determine if a major group HRV could interfere with T cell proliferation, we stimulated PBMC with mitogens, IL-2, allogeneic T cells, or one of four different antigens (tetanus toxoid, VZ, ragweed extract, or streptokinase) in the presence or absence of HRV-16. HRV -16 significantly inhibited T cell proliferation to tetanus, VZ, and ragweed antigens, and it also tended to reduce streptokinase-induced proliferation (figure 1). In contrast, HRV-16 had no effect on proliferative responses to phytohemagglutinin, ConA, or IL-2. The effect on allogeneic T cell proliferation was varied: HRV-16 had no effect on proliferation induced by the TK6 lymphoblastic cell line but tended to reduce proliferation stimulated by irradiated allogeneic PBMe. To determine if the inhibition was dose-dependent, increasing amounts of HRV -16 were incubated with VZ-activated PBMC. As the dose of HRV was increased from 0.1 to 10 TCIDsol cell, VZ-induced T cell proliferation progressively diminished (figure 2).
To confirm findings obtained using PBMC and to define the relevant mechanisms, we next examined the effect of HRV-16 on proliferation of a T cell clone (49.19) that is activated by serotype-specific epitopes of a minor group HRV serotype, HRV-49, but does not proliferate in response to HRV-16 (unpublished data). When HRV-16 was added to a culture of clones in the presence of antigen (irradiated HRV-49) and APCs, there was a reduction in antigen-specific T cell proliferation, and this effect was similar to that produced by ICAM-l MAb ( figure 3 ). HRV-16 that was partially purified to remove products of HeLa cell origin also significantly inhibited T cell proliferation.
To determine if viral replication was required to inhibit T cell proliferation, an aliquot of HRV-16 was divided and half of the viral suspension was UV-irradiated to produce nonreplicative virus particles. Both live and UV -inactivated virus inhibited antigen-specific proliferation of either PBMC (figure 4A) or T cell clone 49.19 (figure 4B) to a similar degree.
Effect of incubating monocytes versus T cells with HRV-16.
To determine if HRV-16 inhibits T cell proliferation through effects on APCs (monocytes) or T cells, we prepared cell suspensions enriched for monocytes or T cells and incubated the purified cells separately with HRV-16 or medium alone. After the cells were washed to remove unbound virus, T cells were added back to the monocytes, and the mixture was stimulated with tetanus toxoid. Tetanus toxoid-driven lymphocyte proliferation was inhibited when monocytes alone or both monocytes and lymphocytes were preincubated with HRV-16 ( figure 5 ). In contrast, proliferation was not inhibited when T lymphocytes alone were preincubated with HRV-16.
Blocking HRV effects with WIN 54954. To determine if HRV -16 inhibited T cell proliferation through an ICAM-1-dependent mechanism and to verify that the effect of the HRV suspension was caused by the virus and not by a HeLa cell product, we used WIN 54954 to block attachment of HRV-16 to ICAM-l. As shown previously, tetanus toxoid-induced proliferation was inhibited by HRV-16; however, WIN 54954 completely blocked the inhibitory effect ofHRV-16 (figure 6).
Effect ofHRV on LPS-induced cytokine secretion. Poliovirus, a closely related picornavirus with a replicative cycle nearly identical to that of HRV, may dramatically inhibit host cell transcription within hours of binding to the cell [8] . To determine whether HRV could inhibit monocyte cytokine secretion, an important costimulatory signal for T cell proliferation, monocytes were activated with LPS in the presence of medium alone, HRV-16, or UV-inactivated HRV-16. TNF-a secretion was not inhibited by either live or inactivated HRV-16, and TNF -a levels tended to be higher in virus-inoculated samples (figure 7) . Additional experiments revealed that IL-l secretion was also unaffected by HRV-16 (data not shown).
Effects of HRV-16 on T cell and NK cell cytotoxicity.
To determine ifHRV-16 could inhibit lymphocyte responses other than T cell proliferation, T cell and NK cell cytotoxicity assays were done using PBMC obtained from 5 healthy subjects in inhibited T cell proliferation triggered by tetanus toxoid (n = 7, * P < .005), varicella antigen (VZ; n = 7, ** P < .001), and ragweed (n = 4, /I P < .05) but had no effect on proliferation secondary to mitogens (combined data represented for phytohemagglutinin and concanavalin A, n = 4 and n = 2, respectively), interleukin-2 (IL-2; n = 6), or irradiated TK6 cells (n = 7). HRV also tended to inhibit proliferation induced by irradiated allogeneic PBMC (n = 6, P = .07) and streptokinase (n = 4, P = . the presence or absence of HRV-16. Coincubation with HRV significantly inhibited T cell cytotoxicity (figure 8A); this effect was noted at all effector-to-target cell ratios (data not shown).
In contrast, NK cell function was not inhibited and, in fact, tended to be slightly enhanced by HRV, although this effect was not statistically significant (P = 0.12; figure 8B ). 
Discussion
Our data demonstrate that HRV -16 inhibits both antigenspecific T cell proliferation and cytotoxicity through an ICAM-I-dependent mechanism. Although HRV inhibits antigen-spe- cific T cell proliferation to antigens, such as tetanus toxoid, VZ , ragweed, and Candida species, it had no effect on T cell proliferation mediated by phytohemagglutinin, irradiated TK6 cells , or IL-2. Since antigens differ from the latter stimuli in that they require processing and major histocompatibility complexrestricted presentation to the T cell, these data suggest that HRV inhibits T cell proliferation through effects on the APC. The normal proliferative responses to IL-2 and mitogen also indicate that HRV is not directly toxic to T lymphocytes, and tended to block proliferation induced by allogeneic PBMC but not by TK6 cells. The difference in these two responses to HRV may be due to differences in surface molecules, because T cell lines, such as TK6, would express relatively little ICAM-I but abundant HLA-DR compared with monocytes and B cells in peripheral blood. These factors would tend to reduce the susceptibility of TK6 cells to the effects of HRV -16.
Both live and UV-irradiated (nonreplicative) HRV-16 effectively inhibited T cell proliferation, providing evidence that viral replication is not required for HRV to inhibit APC function. Furthermore, we [41] and others [42] have been unable to detect HRV replication in PBMC. Purified HRV and virus in HeLa cell supernatant were equally effective in inhibiting T cell proliferation, ruling out the possibility that this was caused by a factor synthesized by infected HeLa cells. Anti-ICAM-l MAb also inhibited T cell proliferation, as previously noted, although the MAb tended to be less effective than HRV. This raises the possibility that, in addition to blocking ICAMl/LFA-I interactions, HRV may also have additional inhibitory effects on APC function, such as inhibiting antigen uptake or processing. We found no evidence, however, that decreased cell proliferation was the result of reduced monocyte cytokine secretion. In addition, although HRV sometimes reduced rates of thymidine incorporation to levels below baseline (SI < I), HRV does not adversely affect the in vitro survival of monocytes [41] or lymphocytes (unpublished data).
The inhibitory action of HRV was dose dependent, and significant inhibition of T cell proliferation occurred when virus concentrations exceeded 0.1 TCIDso/cell, or 5 X 10 4 TCIDsol mL. High titers of HRV (10 3 -10 6 TCIDso/mL) may be found in nasal lavage fluid of infected individuals during the first 3 days of a cold [3] , and considering that the nasal secretions are typically diluted in 5-1 0 mL of normal saline, the amount of HRV in nasal secretions appears to be sufficient to affect ICAM-I-dependent processes in the airway or possibly in regional lymph nodes, where respiratory viruses may be trans-100 10
activation, is also variable [25, 37, 38] . The requirement for ICAM-l/LFA-I binding can be overcome under several conditions, including high-level expression of HLA-DR, large doses of antigen, recruitment of other costimulatory ligand-receptor pairs, or high-affinity binding of antigen-major histocompatibility complex complexes to T cell receptors [25, 38, 39] . These factors may account for some of the variability in the effect of HRV on antigen-driven proliferation.
MAbs specific for ICAM-I have also been reported to block allogeneic T cell activation [37, 40] . We found that HRV-16 ported by afferent lymphoid vessels [43] . It is unlikely, however, that HRV infection, which is localized to the respiratory tract, would inhibit systemic immune responses through this mechanism.
In addition to effects on T cell proliferation, cytotoxic T cell responses were also inhibited by HRV-16. Since proliferation and virus-specific cytotoxicity both contribute to the clearance of respiratory viral infections [44] , inhibiting T cell immune responses may therefore give major group HRVs a competitive advantage in the kinetic race between viral replication and the clearance of virus-infected cells by the immune system. The net result may be prolonged or enhanced HRV replication, producing greater viral shedding and thus an increased likelihood of virus transmission to another host [45] . In contrast to effects on T cells, HRV did not inhibit NK cell responses, despite the fact that ICAM -l/LFA-1 binding can contribute to NK activity under some conditions [46] .
Another possible effect of modulating local immune responses may be to increase the chances of coinfection with other agents. Rhinovirus upper respiratory infections can lead to secondary bacterial infections of the middle ear or sinuses [4~7] , and coinfections with HRV and bacteria may be particularly difficult to treat. For example, Sung and et al. [7] studied 71 patients with combined viral and bacterial otitis and found that the presence of HRV was associated with a higher incidence of therapeutic failure than were respiratory syncytial, parainfluenza, or influenza viruses. Though local tissue swelling, which causes impaired drainage of the sinuses and middle ear, undoubtedly contributes to the high incidence of secondary bacterial and viral infections [47] , inhibition of lymphocyte function may also predispose to local infectious complications.
In summary, major group HRVs, such as HRV-16, can inhibit antigen-specific T cell proliferation, T cell cytotoxicity, and potentially other processes that are dependent on ICAMl/LFA-I binding. This inhibition is likely to occur in the local airway environment, where high titers of HRV may be found during an acute infection. Modulation of ICAM-l-dependent immune responses may give the virus a competitive advantage with the immune system, leading to enhanced viral replication and transmission, and also contribute to the high incidence of other respiratory infections that follow HRV infections.
